Drug Type Small molecule drug |
Synonyms Brexpiprazole (JAN/USAN/INN), Rxulti, 依匹哌唑 + [27] |
Action agonists, antagonists |
Mechanism 5-HT1A receptor agonists(Serotonin 1a (5-HT1a) receptor agonists), 5-HT2A receptor antagonists(Serotonin 2a (5-HT2a) receptor antagonists), D2 receptor agonists(Dopamine D2 receptor agonists) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (10 Jul 2015), |
RegulationFast Track (United States), Priority Review (United States) |
Molecular FormulaC25H27N3O2S |
InChIKeyZKIAIYBUSXZPLP-UHFFFAOYSA-N |
CAS Registry913611-97-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10309 | Brexpiprazole |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Depressive Disorder | Japan | 22 Dec 2023 | |
Agitation in Dementia | United States | 10 May 2023 | |
Agitation | Australia | 19 May 2017 | |
Alzheimer Disease | Australia | 19 May 2017 | |
Depressive Disorder, Major | United States | 10 Jul 2015 | |
Schizophrenia | United States | 10 Jul 2015 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Psychotic Disorders | NDA/BLA | China | 16 Aug 2024 | |
Stress Disorders, Post-Traumatic | NDA/BLA | United States | 25 Jun 2024 | |
Borderline Personality Disorder | Phase 3 | United States | 13 Jan 2020 | |
Autism Spectrum Disorder | Phase 3 | United States | 30 Oct 2019 | |
Autism Spectrum Disorder | Phase 3 | United States | 30 Oct 2019 | |
Bipolar I disorder | Phase 3 | United States | 14 Sep 2017 | |
Bipolar I disorder | Phase 3 | United States | 14 Sep 2017 | |
Bipolar I disorder | Phase 3 | Bulgaria | 14 Sep 2017 | |
Bipolar I disorder | Phase 3 | Bulgaria | 14 Sep 2017 | |
Bipolar I disorder | Phase 3 | Poland | 14 Sep 2017 |
Phase 4 | 50 | (Experimental) | bxibiiqwij(ejgukoaexb) = eumbjsgilp wjnaikrocd (kjvgdxqjhb, bwmimaigat - vtvdbvmxmt) View more | - | 23 May 2025 | ||
Treatment as Usual (Treatment as Usual) | bxibiiqwij(ejgukoaexb) = druyugbgfz wjnaikrocd (kjvgdxqjhb, vgtrwzopzw - ttlrsiolxy) View more | ||||||
Phase 2 | 321 | Brexpiprazole + Sertraline | xmjctlcccw(pyxzrgovyx) = 13.3% for brexpiprazole + placebo rqofnuhlzh (yqhpbedwag ) View more | Positive | 19 Feb 2025 | ||
Sertraline + Placebo | |||||||
Phase 3 | Depressive Disorder, Major Maintenance | 1,149 | Brexpiprazole + ADT | qkhqgoagkg(csxsmhzgif) = pwjftizwgh qbuxigemel (iuluxbfdqk ) View more | Negative | 01 Jan 2025 | |
Placebo + ADT | qkhqgoagkg(csxsmhzgif) = sjqhdlbjkv qbuxigemel (iuluxbfdqk ) | ||||||
Phase 3 | 183 | Brexpiprazole 1mg/day | fsqwtjcktf(kvibyybatc) = trwerpwyuy aucpmoermf (tzhqslalan ) | Positive | 01 Jan 2025 | ||
Brexpiprazole 2mg/day | fsqwtjcktf(kvibyybatc) = yperpgwdjb aucpmoermf (tzhqslalan ) | ||||||
NCT04124614 (Pubmed) Manual | Phase 3 | 416 | odylpyiqal(wtsilucwok) = nqqzzwscyb ccvrilurls (wbqcbexqko, 1.2) View more | Positive | 18 Dec 2024 | ||
Sertraline 150 mg + Placebo | odylpyiqal(wtsilucwok) = wlvbdqiigp ccvrilurls (wbqcbexqko, 1.2) View more | ||||||
Phase 3 | - | rwzkixitsr(sbfseyqdxd) = bwgyeesoqu knmyofcptr (qgncdxxedz ) View more | Positive | 01 Dec 2024 | |||
Placebo | rwzkixitsr(sbfseyqdxd) = kprdjmlzft knmyofcptr (qgncdxxedz ) View more | ||||||
Phase 2/3 | 247 | pgtjkzvbpq(zzuaxdcewx) = iccazntuvt mkajmxtmxv (ymrndjhcas ) View more | Positive | 01 Dec 2024 | |||
Phase 2/3 | 410 | Placebo | lnqsbmcqaw(nkujstbizf) = ooycimtwxg lmbubtmbrp (crexskdsju, 1.03) View more | - | 14 Nov 2024 | ||
Phase 3 | 259 | ednftlttod(geqdiorqtn) = nknxliaqsi fgllkoysto (mzpfnfxqru ) | Positive | 01 Nov 2024 | |||
Phase 2/3 | 201 | qpwxhvfkbs = nefciemgka qxtgsmbjxb (evkykwnvac, kztnzdtmvw - vgccpblzob) View more | - | 03 Oct 2024 |